Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Expresión, extracción y purificación de proteínas recombinantes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20151229003
Publicado:
02/03/2016
Caducidad:
02/03/2017
Resumen:
Una pyme española de biotecnología vegetal especializada en el desarrollo y mejora de nuevos procesos para la producción y purificación de proteínas y otras biomoléculas de origen vegetal ha desarrollado una nueva plataforma para la expresión de proteínas recombinantes en plantas y desarrolla procesos para la extracción, aislamiento y purificación de estas proteínas y la optimización de su uso. La plataforma de expresión de proteínas se basa en el uso de un vector de expresión derivado del virus de una planta, el virus del mosaico del pepino (PepMV). La tecnología utiliza plantas biofábrica en vez de biorreactores para sintetizar las proteínas. La empresa busca socios industriales con el fin de establecer acuerdos comerciales con asistencia técnica.

Details

Tittle:
Expression, extraction and purification of recombinant proteins
Summary:
Spanish SME plant biotech company specialized in the development and scaling of new processes for production and purification of proteins and other biomolecules from plant material, has developed a new platform for the expression of recombinant proteins in plants and develops processes for the extraction, isolation and purification of this proteins as well as the optimization for their use. The SME is looking for an industrial partner to obtain a commercial agreement with technical assistance.
Description:
This company is a biotech company with expertise in proteomics and genomic. It is a spin-off from the university and the Spanish National Research Council (CSIC). The objectives of this company are the development of new technologies for the production of industrial and therapeutic proteins, as well as other biomolecules with applications in biotechnology, biomedicine and food technology.

This company generates knowledge and technology protected by patents, which results in businesses. It participates as a partner with investors, providing the technology for the establishment of industrial process plants.

Its mission, as biotechnology company, is to develop innovative technologies for the production of recombinant proteins over expressed in plants using viral vectors, protected by a CSIC (Spanish National Research Council) patent, exclusively licensed by the company. The company also develops other biomolecules of interest in the fields of biomedicine, food and chemical industry.

The company has developed a new platform for the expression of recombinant proteins in plants and develops processes for the extraction, isolation and purification of this proteins as well as the optimization for their use. The protein expression platform is based on the use of an expression vector derived from a plant virus, Pepino Mosaic Virus (PepMV). This technology uses biofactory plants instead of bioreactors to synthesize the proteins. The technology allows the expression of high levels of protein at low-cost, requires little infrastructure and does not affect the agroecosystem.

The company offers this technology for acquisition, offering support to transfer the technology, to obtain commercial agreement with technical assistance.
Advantages and Innovations:
The main advantages of this technology are:
· The speed for the protein expression, after two weeks the protein can be extracted and purified with a high efficiency.
· The expression of high levels of protein at low-cost.
· The modification of a viral vector for a specific factor is simple and quick.
· The same vector can be used for expressing very diverse proteins.
· The system is ideal for obtaining customized proteins in a few weeks.
· The agroecosystem is not affected.
· The products obtained are free of pathogen or other potential risks, which is particularly important in the case of pharmaceuticals.
· No transgenic plants are used.

Innovative features:
- This technology uses biofactory plants instead of bioreactors to synthesize the proteins.

-The main innovation aspect consists on the ability to produce industrially the recombinant proteins, (both therapeutical and industrial), with a cost 10 times lower to the current cost of the industrial plants for recombinant proteins production, that get these proteins by the over expression method in microorganisms (bacterias -Y- Yeasts), cell culture of mammals, cell culture of plants transgenic plants or animals.
- The technology requires little infrastructure and energy needs.
Stage of Development:
Already on the market
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
The company is looking for biomedicine companies and also food companies to obtain commercial agreement with technical assistance.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002006 Biología sintética
06002001 Bioquímica / biofísica
06002004 Ingeniería de proteínas
06002003 Tecnología de enzimas
06001018 Virus, virología / antibióticos / bacteriología